Effect of Aspirin at the Acute Phase of Cerebral Ischemic Event.

Sponsor

Central Hospital, Nancy, France (Other)

Overall Status

Unknown status

CT.gov ID

NCT01375400

Collaborator

(none)

Enrollment

Location

Study Details

Study Description

Brief Summary

Aspirin is the only anti-platelet medication used at the acute phase of ischemic stroke. The investigators would like to study laboratory effect of the first oral 300 mg dose of aspirin, given at hospital, after an ischemic event.

The principal hypothesis is that platelet activity would be able to recover during this day and could lead to ischemic recurrences.

Two blood samples are accomplished. The first 2 hours after aspirin intake and the second 23 hours after. Photometric aggregometry are performed with arachidonic acid and collagen induced platelet aggregation, measure of thromboxan B2 levels and reticular platelets count.

Condition or Disease	Intervention/Treatment	Phase
Ischemic Stroke	Drug: Aspirin Biological: blood sample	N/A

Study Design

Study Type:

Interventional

Anticipated Enrollment :

50 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Laboratory Effect on Platelet Activity of the First 300 mg Oral Dose Aspirin at the Acute Phase of Cerebral Ischemic Event.

Study Start Date :

Dec 1, 2010

Anticipated Primary Completion Date :

Jul 1, 2011

Outcome Measures

Primary Outcome Measures

Measure of platelet activity recovery within 24 hours after the first 300 mg oral dose of aspirin given at hospital at the acute phase of ischemic stroke [1 month]
We study laboratory parameters of the first 300 mg oral dose of aspirin given, within 48 hours, after ischemic cerebral event. For all patients, two blood sampling are performed, the first, during the third hour after aspirin intake and the second during the twenty-fourth hour. Platelet reactivity is studied on the basis of serum thromboxane B2 levels and light transmission aggregometry after stimulation of platelet-rich plasma by acid arachidonic and collagen 2µg/ml reported to results with collagen 20 µg/ml.

Secondary Outcome Measures

Measure of effect of the first 300 mg oral dose of aspirin given at the acute phase of cerebral ischemic stroke for already aspirin treated [1 month]
For patients already treated with a daily dose of aspirin, a supplementary withdrawn was done before aspirin intake. Platelet reactivity was studied on the basis of serum thromboxane B2 levels and light transmission aggregometry after stimulation of platelet-rich plasma by acid arachidonic and collagen 2µg/ml reported to results with collagen 20 µg/ml.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Adult men and women
Ischemic stroke less than 48 hours
Signed consent

Exclusion Criteria:

Danger to prescription of aspirin (haemorrhagic risk...)
Prescription of heparin or VKA

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Hopital central	Nancy		France	54035

Sponsors and Collaborators

Central Hospital, Nancy, France

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

, ,

ClinicalTrials.gov Identifier:

NCT01375400

Other Study ID Numbers:

Aspirin

First Posted:

Jun 17, 2011

Last Update Posted:

Jun 21, 2011

Last Verified:

Jun 1, 2011

Keywords provided by , ,

aspirin

platelet

Additional relevant MeSH terms:

Ischemic Stroke

Ischemia

Aspirin

Study Results

No Results Posted as of Jun 21, 2011